Prevention and treatment of VZV infections in patients with HIV

Herpes

Volumn 8, Issue 2, 2001, Pages 32-36

  Gershon, A A ^a  

^a Columbia Univ Coll of Physicians ^*  (United States)

Author keywords

Human immunodeficiency virus (HIV); Immunocompromised patient; Patient management; Vaccine; Varicella zoster virus (VZV)

Indexed keywords

ACICLOVIR; ANTIRETROVIRUS AGENT; HERPES ZOSTER IMMUNOGLOBULIN; VALACICLOVIR; VARICELLA ZOSTER VACCINE;

ARTICLE; CHICKENPOX; DRUG INDICATION; DRUG SAFETY; HERPES ZOSTER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOPROPHYLAXIS; INCIDENCE; INFECTION PREVENTION; PRIORITY JOURNAL; SIDE EFFECT; VACCINATION; VARICELLA ZOSTER VIRUS;

ACYCLOVIR; ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIVIRAL AGENTS; CHICKENPOX; CHICKENPOX VACCINE; CHILD; FOSCARNET; HERPESVIRUS 3, HUMAN; HUMANS; PROSPECTIVE STUDIES; RISK FACTORS;

HERPES; HERPES ZOSTER; HUMAN HERPESVIRUS 3; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0034930848     PISSN: 09697667     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Varicella in children with cancer: 77 Cases
2. Varicella-zoster virus infections in children infected with human immunodeficiency virus
3. Varicella and zoster in children with human immunodeficiency virus infection
4. Varicella-zoster virus infection in children with underlying HIV infection
5. Continuous varicella-zoster infection associated with acyclovir resistance in a child with AIDS
6. Herpes zoster, immunological deterioration and disease progression in HIV-1 infection
7. Herpes zoster: A possible early clinical sign for development of acquired immunodeficiency syndrome in high-risk individuals
8. Hyperkeratotic varicella zoster virus infection in an HIV-infected patient. Successful treatment of persistent lesions with cryosurgery
9. Recrudescence of initial cutaneous lesions after crusting of chickenpox in an adult with advanced AIDS suggests prolonged local viral persistence
10. Prolonged cutaneous herpes zoster in acquired immunedeficiency syndrome
11. Emergence of acyclovir-resistant varicella zoster virus in an AIDS patient on prolonged acyclovir therapy
12. The latent herpes simplex virus type 1 genome copy number in individual neurons is virus strain specific and correlates with reactivation
13. The comparative biology of latent herpes simplex virus type 1 and type 2 infections: Latency-associated transcript promoter activity and expression in vitro in infected mice
14. Cell-mediated immunity to varicella-zoster virus
15. Herpes zoster infection in HIV-seropositive patients associated with highly active antiretroviral therapy
16. Zoster incidence in HIV-infected hemophiliacs and homosexual men 1984-1997
17. Restoration of cytomegalovirus-specific CD4+ T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1
18. Changes in the natural history of cytomegalovirus retinitis following the introduction of highly active antiretroviral therapy
19. Decrease of cytomegalovirus replication in human immunodeficiency virus infected-patients after treatment with highly active antiretroviral therapy
20. Polymarase chain reaction detection and clinical significance of varicella-zoster virus in cerebrospinal fluid from human immunodeficiency virus-infected patients
21. Impact of CSF PCR on the management of HIV-infected patients with VZV infection of the CNS
22. Unsuspected varicella-zoster virus encephalitis in a child with acquired immunodeficiency syndrome
23. Brain stem encephalitis due to varicella-zoster virus in a patient with AIDS
24. AIDS-related varicella zostar meningo-encephalitis and radicular pain without cutaneous eruption
25. Childhood AIDS, varicella-zoster, and cerebral vasculopathy
26. Chronic varicella-zoster virus myelitis without cutaneous eruption in a patient with AIDS: Report of a fatal case
27. Management of varicella zoster virus retinitis in AIDS
28. Varicella-zoster virus
29. Use of polymerase chain reaction (PCR) assay to identify and type varicella zoster virus
30. Diagnosis and typing of varicella-zoster virus (VZV) in clinical specimens by polymerse chain reaction (PCR)
31. Visceral varicella zoster infection after bone marrow transplantation without skin involvement and the use of PCR for diagnosis
32. Therapeutic approaches to varicella-zoster virus infections
33. Acyclovir: A decade later
34. Therapy for varicella-zoster virus infections: Where do we stand?
35. Effect of oral acyclovir on pain resolution in herpes zoster: A reanalysis
36. Recent advances in the therapy and prevention of CMV infections
37. A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection
38. Management of acyclovir-resistant herpes simplex and varicella-zoster infections
39. Adverse effects and drug interactions of clinical importance with antiviral drugs
40. Clinical efficacy of high-dose acyclovir in patients with human immunodeficiency virus infection: A meta-analysis of randomized individual patient data
41. The prophylactic role of intravenous and long-term oral acyclovir after allogenic bone marrow transplantation
42. Varicella-zoster infection after allogeneic bone marrow transplantation: Incidence, risk factors and prevention with low-dose aciclovir and ganciclovir
43. Successful treatment of varicella zoster virus meningoencephalitis in patients with AIDS: Report of four cases and review
44. Varicella-zoster ventriculo-encephalitis and spinal cord infarction in a patient with AIDS
45. Herpes varicella zoster encephalitis in immunocompromised patients
46. Live vaccine used to prevent the spread of varicella in children in hospital
47. Live attenuated varicella vaccine
48. The post-marketing safely profile of varicella vaccine
49. Administration of varicella vaccine to HIV-infected children
50. Prevention of varicella
51. The incidence of zoster after immunization with live attenuated varicella vaccine. A study in children with leukemia
52. Live attenuated varicella vaccine: Evidence that the virus is attenuated and the importance of skin lesions in transmission of varicella-zoster virus
53. Use of a live attenuated varicella vaccine to boost varicella-specific immune responses in seropositive people 55 years of age and older: Duration of booster effect